Validation of a Questionnaire in the French Language for the Patient Experience in Radiotherapy

NCT ID: NCT07133594

Last Updated: 2025-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-07

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

More than 50% of cancer patients have radiotherapy (RT) as part of their care pathway. Scientific and technological advances leads to an increase in demand. The development of hypofractionation is also increasing the capacity to treat more patients. These transformations raise questions from an organizational point of view, the quality of care and the response to patient needs.

Several publications highlight that evaluating patient's experience, satisfaction, and collecting their ideas are excellent foundations for delivering patient-centered care (3,4). To assess the patient experience in RT, Olausson et al. developed and validated a questionnaire in English. To this day , this questionnaire has not been validated in French.

The main objective is to validate the psychometric property of reliability of the Radiotherapy Experience Questionnaire (RTEQ) after its adaptation into French. This project also includes an assessment of patient satisfaction regarding their RT care pathway.

This study is part of a broader initiative aimed at redesigning the patient journey in radiotherapy, and innovating in the tools and in the overall care approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There will be 4 steps in this study.

* Phase 1: the RTEQ has been adapted into French by a working group. Phase alreaday completed.
* Phase 2: this is the RTEQ pre-test translated into French. Currently in progress. Comprehension of the questionnaire will be assessed in 50 patients at the Centre Leon Berard (CLB) to obtain the final French version. Patients will complete the RTEQ and a debriefing questionnaire at a time. Patients undergoing hypofractionated RT (between 2 and 10 sessions) as well as patients with more than 11 sessions will be included. Patients undergoing hypofractionated RT will complete the questionnaire at the penultimate session. Patients with at least 11 sessions will be included and will complete the questionnaire during the last week of treatment. The debriefing questionnaire has been developed to determine whether the questionnaire is too long, whether each questions are clear and comprehensive or not.
* Phase 3: pre-test analysis. A descriptive analysis of the responses to each item, as well as the debriefing questionnaire, will be carried out. A meeting with the working group will decide on the necessary modifications for a final version.
* Phase 4: Paucicentric study + validation of the psychometric properties of the RTEQ in French.

Patients will complete the RTEQ and the EORTC PATSAT-C33 questionnaire.

* Group 1: For patients undergoing hypofractionated RT: one measurement period, between Days 2 and 7 (Time n°1).
* Group 2: For patients with at least 11 sessions, two measurement periods: during the first week between Days 2 and 7 (Time n°1) and then during the last week (Time n°2).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Validation RTEQ (RadioTherapy Experience Questionnaire) in French Patients Requiring Radiotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Questionnaires for patients receiving 10 or fewer radiotherapy sessions_

Patients receiving 10 or fewer radiotherapy sessions: Patient will complete two questionnaires only once between Day 2 and Day 7.

Group Type EXPERIMENTAL

RTEQ (RadioTherapy Experience Questionnaire) in French

Intervention Type OTHER

Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

EORTC PATSAT-C33 questionnaire

Intervention Type OTHER

Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

Questionnaires for patients receiving 11 or more radiotherapy sessions_

Patients receiving 11 or more radiotherapy sessions. They will complete two questionnaires, at two measurement times: between Day 2 and Day 7 and then during the last week.

Group Type EXPERIMENTAL

RTEQ (RadioTherapy Experience Questionnaire) in French

Intervention Type OTHER

Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

EORTC PATSAT-C33 questionnaire

Intervention Type OTHER

Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RTEQ (RadioTherapy Experience Questionnaire) in French

Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

Intervention Type OTHER

EORTC PATSAT-C33 questionnaire

Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years
* Patient requiring curative external radiotherapy (at least 2 sessions)
* Patient covered by a medical insurance
* Patient informed and not opposing to the study

Exclusion Criteria

* Patient who don't understand or can't read French
* Any congitive impairment or condition likely to limit the use of scales and questionnaires
* Patient requiring tutorship or curatorship or patient deprived of liberty
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Leon Berard

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sophie BOISBOUVIER, Msc R&I in Healthcare (RT)

Role: PRINCIPAL_INVESTIGATOR

Centre Leon Berard

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Leon Berard

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A02830-47

Identifier Type: OTHER

Identifier Source: secondary_id

ET24-354 - QF-EXPERT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Toxicity of SCART
NCT06341257 WITHDRAWN NA